Related Experiment Video

Updated: Mar 28, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

New active drugs for the treatment of advanced colorectal cancer

Alberto Zaniboni1

  • 1Alberto Zaniboni, Medical Oncology Unit, Fondazione Poliambulanza, 25124 Brescia, Italy.

World Journal of Gastrointestinal Surgery
|January 6, 2016
PubMed

Insights

Newer drugs like aflibercept, ramucirumab, Tas-102, and regorafenib offer new hope for metastatic colorectal cancer patients. These treatments provide effective disease control, even after other therapies have failed.

Area of Science:

  • Medical Oncology
  • Pharmacology
  • Gastrointestinal Oncology

Background:

  • Metastatic colorectal cancer (mCRC) treatment has advanced with new drug classes.
  • Standard chemotherapy regimens like FOLFOX and FOLFIRI are foundational.
  • Prior treatments may include bevacizumab, impacting subsequent therapy choices.

Purpose of the Study:

  • To review recent advancements in pharmacological treatments for metastatic colorectal cancer.
  • To evaluate the efficacy of newer agents as second-line or later-line therapies.
  • To discuss the potential for re-challenging previously administered treatments.

Main Methods:

  • Review of clinical trial data and published literature on newer mCRC drugs.
  • Analysis of efficacy and safety profiles of aflibercept, ramucirumab, Tas-102, and regorafenib.
  • Exploration of treatment sequencing and re-challenge strategies.

Main Results:

  • Aflibercept and ramucirumab show promise as second-line options in combination with FOLFIRI for patients progressing after FOLFOX +/- bevacizumab.
  • Tas-102 and regorafenib demonstrate disease control in heavily pre-treated mCRC patients.
  • Re-introduction or re-challenge with prior therapies after failure of later-line agents is a developing concept.

Conclusions:

  • Emerging therapies offer significant benefits for patients with advanced colorectal cancer.
  • Personalized treatment strategies incorporating these newer agents are crucial.
  • Further research into optimal sequencing and re-challenge protocols is warranted.
Keywords:
AfliberceptColorectal cancerRamucirumabRegorafenibTas-102

More Related Videos

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.8K
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

3.0K

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
611
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
663
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
862
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.2K